Evaluation of Surface Contamination of Bacteria in Various Dental Clinics with Special Reference to Obligate and Facultative Anaerobic Spore Bearing Bacilli

The occupational health and safety is an important prerequisite in dental clinic setup for wellbeing of both the doctor and patient. Both the patient and dentist are always at the risk of infections. Aim and objectives: There is no proper literature on the survey of bacterial spores, especially of Clostridium species in dental clinics. Hence an attempt has been made in the present pilot study to evaluate the surface contamination with special reference to bacterial spores. Materials and methods: Various dental clinics from Chennai city, India were selected for the present study. Samples were collected from two clinics each from endodontic, prosthodontic, orthodontic, and periodontic. In each clinic important places were selected for sampling. The samples were collected in the form of swabs. The swabs thus obtained were inoculated into Robertson Cooked Meat Medium and was incubated in anaerobic condition at 370C for 7 days. Each day the tubes were examined for turbidity and colour change and were noted. At the end of 7th day, the smear was prepared from each tube and gram staining was performed. The gram stained slides were examined microscopically for the presence of spore bearing bacilli especially with special reference to terminal spore bearing bacilli. Results and conclusion: From the present study it is clear that the dental clinics invariably possess a lot of aerobic and anaerobic spores irrespective of stringent disinfection procedures. Hence it is mandatory for the dental clinics to undergo periodical microbiological surveillance and to take proper steps in the control of bacterial spores

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival